Original language | English (US) |
---|---|
Pages (from-to) | 295-298 |
Number of pages | 4 |
Journal | Bone Marrow Transplantation |
Volume | 57 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2022 |
All Science Journal Classification (ASJC) codes
- Hematology
- Transplantation
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Bone Marrow Transplantation, Vol. 57, No. 2, 02.2022, p. 295-298.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients
AU - Tan, Carlyn Rose
AU - Estrada-Merly, Noel
AU - Landau, Heather
AU - Lekakis, Lazaros
AU - Banerjee, Rahul
AU - Mian, Hira
AU - Usmani, Saad Z.
AU - Hanbali, Amr
AU - Lazarus, Hillard M.
AU - Kyle, Robert A.
AU - Dholaria, Bhagirathbhai
AU - Bal, Susan
AU - Strouse, Christopher
AU - Murthy, Hemant S.
AU - Wirk, Baldeep
AU - Nishihori, Taiga
AU - Kumar, Shaji
AU - Shah, Nina
AU - Qazilbash, Muzaffar
AU - D’Souza, Anita
N1 - Funding Information: The research reported in this publication was supported by K23 HL141445 (AD). The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research; support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Angiocrine Bioscience; Astellas Pharma US; Bluebird Bio, Inc.; Bristol Myers Squibb Co.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Eurofins Viracor; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd.; Genentech Inc; GlaxoSmithKline; Incyte Corporation; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Medac GmbH; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Tscan; Vertex; Vor Biopharma; Xenikos BV. Funding Information: Dr. Dholaria reports institutional research support from Takeda, Janssen, Angiocrine, Pfizer, Poseida. Údvisory board for Jazz. Dr. Banerjee reports grants from Pack Health, personal fees from SparkCures, outside the submitted work. Dr. Mian reports grants from Janssen and consulting fees from Janssen, BMS, Takeda, Sanofi, Amgen, GSK. Personal fees from Amgen, Sanofi, BMS/Celgene, Janssen. Board of directors for Myeloma Canada. Dr. Tan reports other financial interests—spouse employed by Janssen R&D. Dr. Usmani reports grants and personal fees from Amgen, personal fees from Abbvie, grants from BMS, grants and personal fees from Celgene, personal fees from MundiPharma, grants from Pharmacyclics, grants and personal fees from Sanofi, grants and personal fees from Seattle Genetics, grants and personal fees from Janssen, grants and personal fees from Takeda, grants and personal fees from SkylineDX, grants and personal fees from Merck, grants and personal fees from GSK, outside the submitted work. Dr. Murthy reports board participation for CRISPR Therapeutics. Dr. Qazilbash reports data safety board participation for Autolus and the advisory board for Oncopeptides. Dr. Dholaria reports institutional research funds from Janssen, Poseida, Angiocrine, Takeda. Personal advisory funds from Jazz. Dr. Kumar reports institutional research support for clinical trials from Abbvie, Celgene, Janssen, Takeda, Adaptive, KITE, Medimmune/Astra Zeneca, Merck, Novartis, Roche, and Sanofi. Advisory board participation paid to the institution from Abbvie, Celgene, Janssen, Takeda, Adaptive, KITE, and Medimmune/Astra Zeneca and Oncopeptides independent review committee. Dr. Nishihori reports research support outside of the submitted work paid to the institution from Norvartis and Karyopharm. Dr. Strouse reports consulting fees from Bristol Meyer Squibb. Dr. Landau reports grant support from Takeda Pharmaceuticals, payment or honoraria from Genzyme corporation. Participation on board for Janssen, Genzyme, Celgene. Dr. D’Souza reports grant support from Takeda, TeneoBio, Sanofi, Caelum and Prothena, consulting fees from Janssen, and advisory board participation fees from Imbrium, Pfizer and BMS.
PY - 2022/2
Y1 - 2022/2
UR - http://www.scopus.com/inward/record.url?scp=85119447622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119447622&partnerID=8YFLogxK
U2 - 10.1038/s41409-021-01527-z
DO - 10.1038/s41409-021-01527-z
M3 - Letter
C2 - 34802047
AN - SCOPUS:85119447622
SN - 0268-3369
VL - 57
SP - 295
EP - 298
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 2
ER -